Acknowledgements

The European Society for Medical Oncology (ESMO) wishes to thank Amgen (Europe) GmbH for donating the content of this section on the Management of Skin Toxicity from EGFR Inhibitor Therapies.

ESMO only accepts content from third parties after careful evaluation of its educational and scientific relevance to the ESMO target audience. Eligible material should meet the essential criterion of non-promotional intent. Such material may be published in other resources, but the content donor has given permission to ESMO for use in OncologyPRO.

At the time of the creation of this content, there were no clinical study outcome-based guidelines for the management of these dermatological toxicities. As such, treatment algorithms here were largely compiled from expert statements, literature review (of review articles, reports of small cohort studies and limited data from small prospective, randomised clinical trials) and expert guidance from a dermatologist, Professor Siegfried Segaert (University Hospital Leuven, Leuven, Belgium), and an oncology nurse Liesbeth Lemmens (University Hospital Leuven, Leuven, Belgium).

Last update: 10 May 2013